One in six men with biopsy-determined grade group 1 (GG1) prostate cancer has non-low-risk disease when clinical data are also considered, putting them at increased risk for prostate cancer-specific mortality, show data from a population-based study led by researchers at Weill Cornell Medicine.

“The results highlight that within the current diagnostic paradigm, biopsy histology alone does not adequately capture long-term prognosis because [prostate cancer-specific mortality] significantly increases across risk groups,” write Neal Patel, MD, urologic oncologist at Weill Cornell Medicine and New York-Presbyterian, and co-authors in JAMA Oncology . “Therefore, terminology and communication with patients regarding the malignant potential of GG1 [prostate cancer] on biopsy must be contextu

See Full Page